pexastimogene devacirepvec
Biologicalexperimental
JX-594 is an oncolytic virus is designed to target and destroy cancer cells. It is also known as Pexa-Vec, INN pexastimogene devacirepvec) and was constructed in Dr. Edmund Lattime's lab at Thomas Jefferson University, tested in clinical trials on melanoma patients, and licensed and further developed by SillaJen. — Wikipedia
Clinical trial activity
18 trials · 20 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
11
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2006 (NCT00629759)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Renal Cell · Phase 1
- Colorectal Neoplasms · Phase 2
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 1
- Lymphoma · Phase 1
- Melanoma · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1/Phase 2
- Neuroblastoma · Phase 1
- Ovarian Neoplasms · Phase 2
- Rhabdomyosarcoma · Phase 1
- Sarcoma · Phase 1/Phase 2
- Sarcoma, Ewing · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Wilms Tumor · Phase 1
Mechanism of action
- Unspecified targetOTHER
Oncolysis - selective infection and killing of tumor cells
- Oncolytic virusOTHER
Oncolytic virus other
- Tumor cell linesOTHER
Tumor cell lines other
- Granulocyte-macrophage colony-stimulating factorVACCINE ANTIGEN
Granulocyte-macrophage colony-stimulating factor vaccine antigen
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPexastimogene devacirepvec ↗
- ChEMBLCHEMBL3039547 ↗
Also known as
- jx-594
- jx-594
- pexastimogene devacirepvec
- pexastimogene devacirepvec
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03294083 | Phase 1 | Jun 7, 2018 | Regeneron, SillaJen, Inc. |
| NCT03206073 | Phase 1/Phase 2 (Phase 2) | Dec 7, 2017 | National Cancer Institute (NCI) |
| NCT02977156 | Phase 1 | Jan 3, 2017 | Centre Leon Berard, Transgene |
| NCT02562755 | Phase 3 | Oct 1, 2015 | SillaJen, Inc. |
| NCT02630368 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Fondation ARC, Institut Bergonié, National Cancer Institute, France |
| NCT02017678 | Phase 2 | Jan 1, 2014 | Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, Canada, Ontario Institute for Cancer Research, University of Toronto |
| NCT01636284 | Phase 2 | Jun 1, 2012 | Jennerex Inc. |
| NCT01394939 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2012 | Jennerex Inc., Transgene, University of Ottawa |
| NCT01329809 | Phase 2 | Oct 1, 2011 | Jennerex Inc., University of Ottawa |
| NCT01169584 | Phase 1 | Aug 1, 2010 | Jennerex Inc., University of Cincinnati |
| NCT01469611 | Phase 1 | Jul 1, 2010 | Sungkyunkwan University |
| NCT01380600 | Phase 1 | Jul 1, 2010 | Jennerex Inc., Sungkyunkwan University |
| NCT01171651 | Phase 2 | Aug 1, 2009 | Jennerex Inc. |
| NCT01387555 | Phase 2 | Dec 1, 2008 | Jennerex Inc. |
| NCT00554372 | Phase 2 | Aug 1, 2008 | Jennerex Inc., Pusan National University, University of California, San Diego |
| NCT00625456 | Phase 1 | Jun 1, 2008 | Jennerex Inc. |
| NCT00429312 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2007 | Billings Clinic, Jennerex Inc. |
| NCT00629759 | Phase 1 | Jan 1, 2006 | Green Cross Corporation, Jennerex Inc. |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (20)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jennerex Inc. | For profit | 11 | 11 | 2 | 2006 |
| SillaJen, Inc. | For profit | 2 | 2 | 2 | 2015 |
| Sungkyunkwan University | Academic/Hospital | 2 | 1 | 1 | 2010 |
| Transgene | For profit | 2 | 0 | 2 | 2012 |
| University of Ottawa | Academic/Hospital | 2 | 0 | 1 | 2011 |
| Billings Clinic | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Centre Leon Berard | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Fondation ARC | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Green Cross Corporation | For profit | 1 | 0 | 1 | 2006 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Institut Bergonié | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Mount Sinai Hospital, Canada | Academic/Hospital | 1 | 1 | 1 | 2014 |
| National Cancer Institute, France | Government | 1 | 0 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2017 |
| Ontario Institute for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Pusan National University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Regeneron | For profit | 1 | 0 | 1 | 2018 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2014 |
20 organizations
Page 1 / 1